Plasma catecholamine release-inhibitory peptide catestatin in patients with essential hypertension

Journal of Cardiovascular Medicine

Volumn 12, Issue 9, 2011, Pages 643-647

  Meng, Lei ^a   Ye, Xiao Jin ^a   Ding, Wen Hui ^a   Yang, Ying ^a   Di, Bei Bing ^a   Liu, Lin ^a   Huo, Yong ^a  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

Author keywords

catestatin; essential hypertension; left ventricular hypertrophy

Indexed keywords

CATESTATIN; GLUCOSE; LIPID; NORADRENALIN;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; ECHOCARDIOGRAPHY; ESSENTIAL HYPERTENSION; FEMALE; GLUCOSE BLOOD LEVEL; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NORADRENALIN BLOOD LEVEL; PROTEIN BLOOD LEVEL;

AGED; BIOLOGICAL MARKERS; BLOOD PRESSURE; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; CHINA; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMOGRANIN A; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MALE; MIDDLE AGED; NOREPINEPHRINE; PEPTIDE FRAGMENTS; PROSPECTIVE STUDIES; UP-REGULATION;

EID: 80051792672     PISSN: 15582027     EISSN: 15582035     Source Type: Journal    
DOI: 10.2459/JCM.0b013e328346c142     Document Type: Article

References (18)

1. Mahapatra NR. Catestatin is a novel endogenous peptide that regulates cardiac function and blood pressure. Cardiovasc Res 2008; 80:330-338.
2. Kennedy BP, Mahata SK, O'Connor DT, Ziegler MG. Mechanism of cardiovascular actions of the chromogranin A fragment catestatin in vivo. Peptides 1998; 19:1241-1248. (Pubitemid 28475128)
3. Mazza R, Gattuso A, Mannarino C, et al. Catestatin (chromogranin A344- 364) is a novel cardiosuppressive agent: inhibition of isoproterenol and endothelin signaling in the frog heart. Am J Physiol Heart Circ Physiol 2008; 295:H113-H122.
4. Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978; 58:1072-1083. (Pubitemid 9091990)
5. Devereux RB, Alonso DR, Lutas EM, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986; 57:450-458. (Pubitemid 16119719)
6. Ganau A, Devereux RB, Roman MJ, Gonzalez M, Landaeta A. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. J Am Coll Cardiol 1992; 19:1550-1558.
7. European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension- European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21:1011-1053.
8. Grassi G, Quarti-Trevano F, Dell'oro R, Mancia G. Essential hypertension and the sympathetic nervous system. Neurol Sci 2008; 29:S33-S36. (Pubitemid 351836959)
9. Taupenot L, Harper KL, O'Connor DT. The chromogranin-secretogranin family. N Engl J Med 2003; 348:1134-1149. (Pubitemid 36337325)
10. Mahata SK, O'Connor DT, Mahata M, et al. Novel autocrine feed back control of catecholamine release. A discrete chromogranin a fragment is a noncompetitive nicotinic cholinergic antagonist. J Clin Invest 1997; 100:1623-1633. (Pubitemid 27425790)
11. Kruger PG, Mahata SK, Helle KB. Catestatin (CgA3442364) stimulates rat mast cell release of histamine in a manner comparable to mastoparan and other cationic charged neuropeptides. Regul Pept 2003; 114: 29-35. (Pubitemid 36588674)
12. Mahata SK, Mahata M, Parmer RJ, O'Connor DT. Desensitization of catecholamine release. The novel catecholamine release-inhibitory peptide catestatin (chromogranin a3442364) acts at the receptor to prevent nicotinic cholinergic tolerance. J Biol Chem 1999; 274:2920-2928. (Pubitemid 29075379)
13. Egger M, Beer AG, Theurl M, et al. Monocyte migration: a novel effect and signaling pathways of catestatin. Eur J Pharmacol 2008; 598:104-111.
14. Radek KA, Lopez-Garcia B, Hupe M, et al. The neuroendocrine peptide catestatin is a cutaneous antimicrobial and induced in the skin after injury. J Invest Dermatol 2008; 128:1525-1534. (Pubitemid 351693209)
15. Mahata SK, Mahata M, Wakade AR, O'Connor DT. Primary structure and function of the catecholamine release inhibitory peptide catestatin (chromogranin A(344-364)): identification of amino acid residues crucial for activity. Mol Endocrinol 2000; 14:1525-1535.
16. Mahapatra NR, O'Connor DT, Vaingankar SM, et al. Hypertension from targeted ablation of chromogranin A can be rescued by the human ortholog. J Clin Invest 2005; 115:1942-1952. (Pubitemid 40979734)
17. O'Connor DT, Kailasam MT, Kennedy BP, Ziegler MG, Yanaihara N, Parmer RJ. Early decline in the catecholamine release-inhibitory peptide catestatin in humans at genetic risk of hypertension. J Hypertens 2002; 20:1335-1345. (Pubitemid 34925678)
18. Vaingankar SM, Li Y, Biswas N, et al. Effects of chromogranin A deficiency and excess in vivo: biphasic blood pressure and catecholamine responses. J Hypertens 2010; 28:817-825.